RecruitingNCT06971458

Endometrioma Ethanol Sclerotherapy - Prospective Cohort Study Protocol

Endometrioma Ethanol Sclerotherapy and Its Effect on Ovarian Function and Fertility Treatment Outcome - Prospective Cohort Study Protocol


Sponsor

Hillel Yaffe Medical Center

Enrollment

120 participants

Start Date

Aug 9, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Ovarian endometriomas are cystic masses lined with endometrial tissue that contains fluid arising from a collection of menstrual debris. Ovarian endometriomas clinical manifestations includes pelvic pain, dysmenorrhea, dysfunctional uterine bleeding, and infertility. Endometriomas are most commonly treated either medically or by surgical excision. Ultrasonography (US)-guided aspiration and sclerotherapy is a new approach. Its mechanism of action is believed to be destruction of the inner epithelial lining, which is followed by inflammation and fibrosis, eventually resulting in regression of the cyst. The main advantage in this approach is the avoidance of collateral damage to the ovary.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 41 Years

Inclusion Criteria1

  • A woman with endometrioma with a diameter of 25-100 mm

Exclusion Criteria1

  • Other causes of infertility (sperm disorder, ovulation disorder, uterine disorder, mechanical factor, poor ovarian reserve)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURESclerotherapy

ultrasound (US)-guided sclerotherapy for the treatment of ovarian endometrioma


Locations(1)

Hillel Yaffe Medical Center

Hadera, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06971458


Related Trials